Podcasts about GIP

“Obesity Rx

Today's episode dives into Retatrutide—the upcoming “Triple G” weight loss medication creating major buzz. Dr. Lisa shares the science behind this powerful GLP-1 / GIP / glucagon receptor agonist, explains why it's being called the “Taylor Swift of meds,” and answers common questions from a recent women's summer event. From dramatic weight loss results to calming relentless food noise, we explore why Retatrutide may redefine obesity treatment—and why support, not just medication, is key for long-term health, longevity, and weight loss success. Whether you're on a weight loss med, considering one, or just curious, this episode gives you the scoop you'll want before everyone else is talking about it.If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

In recent years, the fitness industry has witnessed a notable surge in the utilization of GLP-1 and now also GIP agonists, as a novel approach to enhance weight loss outcomes.In today episode I'm revisiting the topic (I did another episode on GLP-1s in Season 2, you can find that episode HERE) of GLP-1s. I will be discussing:The surprising usage statistics and rapid increase in prevalence of this drug classThe widespread misuse, and over prescription of this drugWhat the use of these drugs says about how society views the obesity epidemicHow GLP-1 impacts motility in the GI tract and those long term consequenceswho might benefit most from these medications, versus who should steer clear My personal thoughts  __________________________________________Join me on the 'gram! Get free recipes and tips delivered right to your inbox every Friday!Learn more about your options for working 1:1 with me: https://www.revivewellness.health/services Schedule a free call with me hereTry Syntrax! To try to the most delicious, gluten free, lactose free "top of the line" whey isolate AND save 25% use the code "syntraxallison" at checkout.Want some FREE LMNT? Use this link for a FREE sample pack with any order!Better Bodies discount code "BB15" at checkout to save 15% on my favorite betterbodies gear! Save 10% on PureFactorFormulations supplements with my code "Revive10" at checkout!

The words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology's annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech's solid tumor bispecific BNT327. Elsewhere, Sanofi nabbed the year's second-biggest buyout, picking up Blueprint for $9.5 billion, expanding its rare disease portfolio. And Regeneron plunked down up to $2 billion to license a dual GLP-1/GIP receptor agonist from Chinese biopharma Hansoh Pharmaceuticals Group.  Back in Chicago, presentations by AstraZeneca, Gilead and Amgen drew rave reviews from investor analysts, while Pfizer and Arvinas elaborated on mixed data from a PROTAC that showed positive results in only a subsection of breast cancer patients, failing to impress Wall Street. Meanwhile, Bicara's solid survival stats in head and neck cancer weren't enough to clear the high bar set by rival Merus. At the meeting, BioSpace's own Dan Samorodnitsky sat down with Jazz Pharmaceuticals' CMO Rob Iannone to discuss the company's recently acquired pediatric glioma drug, and talked AI strategy with AstraZeneca's head of U.S. oncology for lung cancer Arun Krishna. Dan recaps his ASCO experience here.  Speaking of buzzy therapeutic spaces, there was more action on the vaccines front last week as Health and Human Services Secretary RFK Jr. announced that healthy children and healthy pregnant women would no longer be advised to get vaccinated against COVID-19. However, as of publication, the CDC still recommends a COVID vaccine for healthy children but instead of a universal recommendation advises that the decision should be made between parents and healthcare providers. Against this backdrop, the FDA signed off on Moderna's next-gen COVID-19 vaccine, mNEXSPIKE, for a limited population in line with its new guidelines. This was a much-needed win for Moderna, which last week had a $760 million-plus government contract for its mRNA-based bird flu vaccine terminated.  Also on the policy front, the Trump administration released its Make America Healthy Again report last week to much scrutiny after reports found studies and references that did not exist.  

Mayo ya se va. Y lo sobrevolamos recordando algunas de las novedades favoritas que te hemos presentado a lo largo del mes.(Foto del podcast; Private Function)Playlist;(sintonía) LOST ACAPULCO “México libre” (Death by robots)PRIVATE FUNCTION “Gamma Ray” (A bunch of songs)SPLIT SYSTEM “Quemicals”CYANIDE PILLS “Falling for you”NERVOUS EATERS “No more idols”THE SOUND MINDS “Hide and seek”THE UNTAMED YOUTH “Patty baby” (Gip up and go!)BILLY CHILDISH and THE CHATHAM SINGERS “Beneath the midnight trees” (Step out!)VINICIUS e SEU CONJUNTO SALVAGEM “Vou roubar o seu corasao”BLOODSHOT BILL “Rule book”LOS TORONTOS “Take a bath”LOS MEJILLONES TIGRE “Vente conmigo (el baile del vampiro)” (Me gustó más el libro)GARBAYO “Corre conmigo” (Días de euforia)TY SEGALL “Possession” (Possession)ROBERT FORSTER “All of the time” (Strawberries)ANGELA HOODOO “Fugitivo” (Outlaw girls)JODIE CASH “That light on me” (My senses)NEIL YOUNG and THE CHROME HEARTS “Talkin’ to the trees”Escuchar audio

Jordan Kimler, Nurse Practitioner with Premier U, joined us again in studio, to give us updates on Heidi's weight loss journey, and the difference between GLP-1 and GIP.

Summary In this episode of the Future of Dermatology podcast, Sam Kamangar asks Dr. Faranak Kamangar your burning questions about GLP-1 and GIP medications. They discuss the evolving landscape of dermatology, explore the implications of these medications for weight loss, metabolism, and skin health, as well as the aesthetic considerations and potential side effects associated with their use. The episode emphasizes the importance of understanding who qualifies for these medications and the need for a holistic approach to health and beauty. Takeaways - The conversation around beauty is shifting from surface-level treatments to internal health. - GLP-1 medications are gaining popularity for their weight loss benefits. - FDA-approved medications undergo rigorous testing for safety and efficacy. - Weight loss is a chronic condition that requires ongoing management. - Muscle mass is crucial for maintaining metabolism as we age. - GLP-1 medications can have side effects, including gastrointestinal issues. - Hydration and diet play significant roles in managing side effects of GLP-1 medications. - Aesthetic concerns, such as 'Ozempic face,' are emerging with the use of GLP-1 medications. - Not everyone needs to be on GLP-1 medications; they are for those with obesity or diabetes. - The hype around GLP-1 medications may lead to overuse and shortages for those who truly need them. Chapters 00:00 - Introduction to Dermatology and GLP-1 Medications 03:04 - Understanding GLP-1 and GIP Medications 05:57 - The Role of GLP-1 in Dermatology 08:55 - Who Should Use GLP-1 Medications? 11:59 - Metabolism and Chronic Conditions 14:58 - The Hype Around GLP-1 Medications 17:59 - Aesthetic Considerations with GLP-1 Use 20:49 - Managing Side Effects of GLP-1 Medications

Did you know that some weight loss medications can help people lose up to 20% of their body weight, comparable to bariatric surgery outcomes? In this episode, I dive into the latest research comparing two major weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide), based on findings from the 72-week SURMOUNT-5 trial. I explain how Zepbound led to greater weight loss (about 20.2% vs. 13.7% with Wegovy), possibly due to its dual action on GIP and GLP-1 receptors. Both drugs were generally well tolerated, with similar side effects like nausea and constipation, though Wegovy had slightly more people stop due to GI issues. I also emphasize that while Zepbound may appear more effective, individual needs, such as cardiovascular health or sleep apnea, should guide treatment decisions. Lastly, I remind you that sustainable weight loss requires patience, realistic expectations, and a holistic approach that includes lifestyle changes, not just medication. Tune in to this episode to learn which weight loss medication might be right for you and why your journey to health is more than just the number on the scale.   Episode Highlights: Comparison of Wegovy (semaglutide) and Zepbound (tirzepatide) Average weight loss outcomes and waist circumference changes between both medications Mechanism of action: GLP-1 vs. dual GIP/GLP-1 receptor targeting Side effect profiles and tolerability of both medications FDA approval differences, including cardiovascular risk reduction and sleep apnea treatment Importance of personalized treatment plans and setting realistic weight loss expectations Ongoing research into oral formulations and long-term safety studies Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Such a fascinating and jam-packed conversation with my guy - Calvin Scheller. Calvin has a real talent for breaking down complex science + together we dive into what actually influences our appetite. Topics discussed:-What drives people to eat?-How environment, psychology, and physiology influence what (and how much) we eat.-Defining appetite: what it actually means.-The role of the hypothalamus and brain in assessing our body's needs.-Orexigenic vs. anorexigenic signaling (aka the signals that drive us to eat more or less).-Hormones you've probably heard of - cortisol, serotonin, and dopamine & how they impact hunger.-A deep dive into leptin: what it is, how it works, and what leptin resistance means.-Why people with higher body fat levels might actually experience more hunger, not less.-GLP-1 and GIP: their role in appetite suppression and a discussion around common weight loss medications.+ so much more in-between. I loved this chat + I know you will too!Where to find Calvin: IG: @calvin_schellerTikTok: @physiologywithcalvinCheck out Calvin's Coaching HEREWhere to find me: IG: @lukesmithrdCheck out my website HERETIA for listening!!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. It's an exciting time to be practicing in obesity medicine, with groundbreaking tools like Zepbound and Wegovy helping people achieve their weight loss goals in ways that were once unimaginable. Plus, with new medications like retatrutide (the triple agonists) on the horizon, the future of weight management is looking even brighter.But with so many options available, it can be overwhelming to figure out which medication is right for you. How do Zepbound and Wegovy compare? Can you switch between the two? Is one more effective than the other? In this episode, I'll dive into the key differences between Zepbound (Mounjaro) and Wegovy (Ozempic), comparing doses, effectiveness, and answering all your burning questions about how these medications stack up against each other. ReferencesThe Top 5 Mistakes People Make When Starting GLP-1 Season 1 of the Premium Podcast: The Obesity Guide: Behind the CurtainAudio Stamps00:30 - Dr. Rentea sets the stage for a back-to-basics breakdown of Wegovy vs. Zepbound, which touches on key topics like switching, dosing, and access.01:58 - A comparison of Wegovy (GLP-1) and Zepbound (dual GLP-1 and GIP), discussing their average weight loss effects and varying response rates.05:19 - Dr. Rentea discusses the reasons someone might consider switching medications.06:45 - Switching medications shouldn't involve restarting titration, and working with a knowledgeable physician to manage transitions effectively is key.11:45 - Medication can be a helpful tool, but long-term success depends on working with a skilled physician and staying focused on sustainable progress.Quotes“Within the first few months, it's going to become very clear. Do you need an additional tool? Do we need to tweak things? Do we need to change things?”“These are medications, but they're not everything. You still have to do the heavy lifting on the lifestyle aspect behind the scenes. But you have the ability to switch from one to the other.”“You really should be working with someone who is very familiar with these medications, with switching medications, with adding other things to it, with changing things. There is always something else that can be done.”“We do sometimes see higher results with ZepBound, but there's going to be other medication that comes out that's potentially higher than that. At the end of the day, it's what helps me to keep doing all the other things.”All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.

In this first part of a two-part series, Dr. Saluja and Kane unpack how GLP-1 and GIP medications, including Ozempic, Wegovy, and Mounjaro, are reshaping not just metabolism, but also facial structure, leading to what's now known as "Ozempic Face." In this episode, they explore what GLP-1 receptor agonists and GIP agonists are, how rapid fat loss affects skin, collagen, and volume, and introduce key strategies that can be done at home from a nutritional perspective to support collagen health and overall facial balance. Join them as they break down the science and lay the foundation for more advanced treatment approaches discussed in Part Two. Thank you for your listenership!

Summary Join Dr. Faranak Kamangar as she embarks on the podcast journey of dermatometabolics. For the next few weeks she'll explore various topics in the realm of dermatometabolics such as insulin resistance, GLP and GIP, and skin care. Stay tuned!

So, you've heard the rumors—“GLP-1s destroy your muscle!” But… is that actually true? Think again. Today, we're setting the record straight. If you're serious about real, healthy weight loss—and actually keeping your strength for the long haul—this episode is a must. We're diving into a long-overdue conversation about GLP-1 medications, metabolism, body composition, and what's really happening to your muscle mass on these meds. Because weight loss isn't just about the scale—it's about how you lose it. Let's get into it. Quick Basics — What Are GLP-1 and GIP/GLP-1 Medications? Let's start at ground zero. GLP-1 medications — like semaglutide (Wegovy and Ozempic) — are game-changers for weight loss and diabetes. They work by mimicking gut hormones that regulate appetite, blood sugar, and insulin release. GLP-1 (glucagon-like peptide 1) slows down how fast your stomach empties, helps your body respond better to insulin, and most importantly — makes you feel fuller, longer. Tirzepatide (Mounjaro and Zepbound), also hits GIP receptors — that's glucose-dependent insulinotropic polypeptide — lending to more blood sugar regulation in some people. What Happens to Your Body During Weight Loss? No matter how you lose weight — whether it's from keto, bariatric surgery, or GLP-1 meds — your body isn't just burning fat. It's normal to lose a mix of fat mass and lean mass, which includes muscle, bone, and organ tissue. But the goal with any good weight loss plan is to maximize fat loss and minimize muscle loss. The Myth: “GLP-1s Make You Lose All Your Muscle” Here's the truth: GLP-1 medications do NOT inherently destroy your muscle mass. In fact, clinical studies have shown that GLP-1 medications, like semaglutide, have osteoblastic effects, meaning they can stimulate the activity of osteoblasts, the cells responsible for bone formation. This can potentially help improve bone density and support bone health. While the primary role of GLP-1 medications is to aid in weight loss and improve blood sugar control, these osteoblastic effects may offer additional benefits, especially in individuals at risk for osteoporosis or bone loss. If you see muscle loss during GLP-1 therapy, it's because of rapid overall weight loss and a lack of resistance training and protein — not because the medication is wasting your muscle. It's the same thing we see in ANY rapid weight loss — if you don't stimulate your muscles and feed them the right building blocks, your body gets rid of them because it thinks you don't need them. Muscle is metabolically expensive. Your body is smart — if it thinks you're not using muscle, it's going to save energy and dump it. That's biology — not the medication. Why Protein and Resistance Training Are Non-Negotiable If you're on a GLP-1, your appetite is lower — which is great for fat loss, but it means you could accidentally under-eat protein if you're not paying attention. Protein is literally the raw material your body uses to maintain and build muscle. Protein also helps build and repair tissues and is essential for producing enzymes, hormones, and maintaining a healthy immune system. Without enough, your body will start to break down lean tissue to make up the difference. And without resistance training (e.g., bodyweight exercises), your body assumes you don't need the muscle anymore. Use it or lose it. How to Protect (and Even Build) Muscle on GLP-1s Here's the simple formula: Prioritize protein: Aim for at least 0.8 to 1 grams per pound of body weight per day. Some need even more during active fat loss. Strength train 2–4 times a week: Focus on compound movements — think squats, deadlifts, presses, pulls, push ups, lunges, planks, and wall sits. Don't fear the scale: Remember that as you lose fat and build muscle, the number might not drop as fast — but your body composition is improving (e.g., reduced body fat, more defined muscles, improved waist circumference, increased energy and strength, and don't forget improved cardiovascular health). Think long-term: It's not just about losing weight — it's about keeping a strong, healthy, metabolically active body. THIS is what helps maintain weight loss. Making sustainable lifestyle changes can be challenging, but they are the most important choice you can make when it comes to losing weight and improving your metabolism in the long run. The goal isn't just weight loss — it's fat loss while preserving and strengthening lean mass. It's important to remember that GLP-1s are a powerful tool, but they aren't a magic. You still have to partner with your body — feed it well, move it wisely, and respect the incredible machine it is. Strong, lean, metabolically active — that's the future we're building, not just smaller bodies. Thanks again for listening to The Peptide Podcast. If this episode helped you rethink your game plan, do me a favor — share it with someone who's starting their GLP-1 journey. And as always, have a happy healthy week! Thanks for listening to The Peptide Podcast. If you found this episode helpful, please follow or leave a review. And if there's a topic you'd like to hear more about, feel free to reach out—we'd love to hear from you. As always, have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

In this week's episode, Kirsty and Nicole break down the science behind Ozempic and other GLP-1 weight loss medications—and ask the big question: are these drugs really the answer to long-term weight struggles, or just a short-term fix?With a rise in popularity of medications like Ozempic and Wegovy, it's easy to get caught up in the hype. But behind the dramatic weight loss headlines is a much deeper story. Kirsty and Nicole unpack how these medications work on the brain and gut to suppress appetite, the difference between GLP-1 and GIP hormones, and what sets these drugs apart from older weight loss medications.They also explore the potential downsides—like muscle loss, nutrient deficiencies, mental health changes, and the common rebound effect once people stop taking them. Most importantly, they discuss why these medications don't address the root causes of weight gain, and what to focus on if you're looking for sustainable, long-term results.This episode covers:✅ How Ozempic and other GLP-1 medications actually work✅ The role of gut-derived satiety hormones like GLP-1 and GIP✅ Common side effects and long-term risks of these medications✅ Why many people regain weight after stopping✅ How this new class differs from older weight loss drugs✅ The emotional and hormonal root causes of weight gain✅ Natural ways to support GLP-1 levels and appetite regulation✅ Why addressing metabolism, muscle mass, gut health, and mindset is keyIf you've been considering weight loss medication or are simply curious about how it all works, this episode brings clarity, clinical insight, and a balanced perspective to help you make empowered choices for your health.

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

Inoltre, la sentenza n. 36/2025 della Corte costituzionale in tema di processo tributario, un approfondimento sul D.L. 37/2025 sul rafforzamento dei centri di rimpatrio e un decreto del GIP milanese in materia di responsabilità penale dei genitori in caso di omicidio stradale commesso dal figlio minore.>> Leggi anche l'articolo: https://tinyurl.com/mttactxj>> Scopri tutti i podcast di Altalex: https://bit.ly/2NpEc3w

According to the Centers for Disease Control and Prevention, more than 40% of American adults have obesity, costing the U.S. healthcare system an estimated $173 billion annually. The development of incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), marks a major advance in obesity treatment. Registered Dietitian Nutritionists (RDNs) play a crucial role in providing medical nutrition therapy (MNT) to people using these medications as part of comprehensive obesity care. Tune into this episode to learn about: ●       the new paper published in JAND about injectable weight loss medications and lifestyle interventions ●       the unique and evolving role of RDNs in obesity care ●       why this new class of obesity medications has become so popular ●       how these medications work ●       the amount of weight loss needed to reduce obesity related comorbidities ●       the evolution of different terms for these medications ●       the pipeline of obesity medications we will see in the next few years ●       how these medications have impacted the role of RDNs in counseling patients ●       common side effects and nutritional considerations ●       concerns about loss of muscle mass and bone density ●       the importance of and role of exercise while taking these medications ●       emotional aspects of significant weight loss in a short time ●       how RDNs can be utilized in comprehensive obesity care in the long term ●       how RDNs can stay informed and up to date on the medications and obesity care in general ●       when people taking these medications should be referred to RDNs ●       how working with an RDN can improve a person's experience and outcomes ●       additional information and resources for the public and health professionals Full shownotes, transcript and resources: https://soundbitesrd.com/284          

TOPICS:⁃ WHAT IS GLP-1 & GIP? WHAT ARE THE MECHANISMS BY WHICH THEY HELP WITH WEIGHT LOSS?⁃ CAN WE GO OVER THE CURRENT ANTI-OBESITY MEDICATIONS AVAILABLE AS WELL AS THE ONES THAT WILL BE RELEASED WITHIN THE NEXT FEW YEARS⁃ LIRAGLUTIDE⁃ SEMAGLUTIDE⁃ TIRZEPATIDE⁃ RETRATUTIDE⁃ CAGRISEMA⁃ BIMAGRUMAB⁃ SEX DIFFERENCES IN RESPONSE TO GLP-1 RA'S⁃ WHY WOMEN LOSE FASTER & MORE WEIGHT ON GLP-1'S⁃ WHAT ARE THE MOST COMMON MISTAKES PEOPLE MAKE WHEN USING THESE COMPOUNDS?⁃ HOW TO OPTIMIZE BODY COMPOSITION OUTCOMES WHEN USING GLP-1'S?⁃ WHAT STRATEGIES CAN BE USED TO KEEP THE DOSE LOWER TO KEEP SIDE EFFECTS LOWER?⁃ FAT & WEIGHT LOSS PLATEAUS⁃ WHAT TO DO IF SOMEONE WANTS TO COME OFF? TAPERING OFF GLP'SWHERE TO CONNECT WITH ME:Follow Brandon on IG: https://www.instagram.com/brandondacruz_/Email: Bdacruzfitness@gmail.comFor Info on Brandon's Coaching, Consultation & Mentorship Services: https://form.jotform.com/bdacruzfitness/coachinginquiryBrandon's Website: https://www.brandondacruzfit.comLink To Lyle's New Book: https://www.amazon.com/dp/B0DT26F7HY

President Donald Trump doubled down on tariff threats targeting pharma, saying additional levies on pharmaceuticals will come “at some point,” per CNBC. Meanwhile, Johnson & Johnson became the latest big pharma to respond to Trump's warning of potential tariffs if companies don't reshore their manufacturing, announcing a massive $55 billion U.S. manufacturing and R&D investment. Not all companies are on board, however: AstraZeneca is looking eastward, pumping $2.5 billion into a new research facility in Beijing.    Also on the policy front, Trump nominated acting CDC director Susan Monarez for the top job after pulling his first nominee, Dave Weldon, days before his senate hearing was expected to begin. If confirmed, Monarez would be the first CDC director since 1953 to not have a medical degree; she holds a Ph.D. in microbiology and immunology from the University of Wisconsin.   In weight loss news, Novo Nordisk is paying China-based United Laboratories $200 million upfront to license a triple agonist of the GLP-1, GIP and glucagon receptors that could one day compete with Eli Lilly's retatrutide. And BioSpace examines the next great challenge for GLP-1s: oral formulation manufacturing.    Two more therapeutic spaces in focus last week are Duchenne muscular dystrophy and spinal muscular atrophy, where companies including Dyne Therapeutics, REGENXBIO and Novartis presented new data on their respective candidates. And the Duchenne community continued to react to news of the death of a patient taking Sarepta's approved gene therapy Elevidys.  In cardiovascular news, Alnylam won a much-anticipated approval for Amvuttra as the first RNAi silencer for transthyretin amyloid cardiomyopathy, setting up a three-way race with Pfizer's tafamidis—marketed as Vyndaqel and Vyndama—and BridgeBio's Attruby. Next up is Milestone Therapeutics' CARDAMYST in paroxysmal supraventricular tachycardia, which has a PDUFA date of March 27.   Finally, the saga of Cassava Sciences' Alzheimer's hopeful simufilam is over, as the company announced it has ended development of the controversial candidate.   

MESSINA (ITALPRESS)- I carabinieri del Comando Provinciale di Messina e i Finanzieri dei Comandi Provinciali di Catania e Messina hanno effettuato una vasta operazione nelle Province di Messina e Catania, con l'esecuzione di misure cautelari emesse dai GIP dei Tribunali del capoluogo peloritano e di quello etneo, su richiesta delle rispettive Procure, nei confronti 39 persone, a vario titolo indagate, per associazione a delinquere di stampo mafioso, associazione finalizzata al narcotraffico, numerosi episodi di spaccio di stupefacenti, estorsione, rapina, accesso indebito a dispositivi idonei alla comunicazione da parte di soggetti detenuti - tutti reati commessi con metodo mafioso o con il fine di agevolare il clan “Cappello-Cintorino” - e trasferimento fraudolento di valori.mgg/

In this Metabolic Classroom lecture, Dr. Bikman explores GLP-1 receptor agonists (such as Ozempic and Mounjaro) and how to use them more effectively.Ben first explains how GLP-1 is naturally produced in the gut and helps regulate glucagon suppression, slows gastric emptying, and promotes satiety. However, he highlights research showing that individuals with obesity have a blunted GLP-1 response to carbohydrates, which may contribute to overeating. He suggests that GLP-1 drugs could be used more strategically—not just for general weight loss, but specifically to control carbohydrate cravings.While these drugs can promote rapid weight loss, they can also come with serious trade-offs, including mental health risks (depression, anxiety, and suicidal thoughts), lean mass loss (up to 40% of weight lost), diminishing effects over time, and digestive complications such as gastroparesis (stomach paralysis). He critiques the current high-dose, long-term approach to these medications, arguing that most people are not using them strategically and eventually regain lost weight—primarily as fat.Dr. Bikman proposes a better approach to using GLP-1 drugs that focuses on low-dose, short-term usage to help control carbohydrate cravings, rather than suppressing appetite completely.His four-step plan includes: (1) starting at the lowest effective dose, (2) engaging in resistance training to preserve muscle mass, (3) adopting a low-carb, high-protein diet, and (4) cycling off the drug after 3-6 months to assess whether cravings remain under control. He also discusses newer GLP-1/GIP dual agonists like Tirzepatide, which may be even more effective but still require careful usage.In closing, Ben emphasizes that GLP-1 drugs should be a tool, not a crutch.The ultimate goal should be to regain control over eating habits, build long-term dietary discipline, and use the drug only when needed. He encourages those considering these medications to work closely with their healthcare providers and approach them with a long-term metabolic health strategy in mind.Show Notes/References:For complete show notes and references referred to in this episode, we invite you to become a Ben Bikman Insider subscriber. As a subscriber, you'll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben, ad-free Metabolic Classroom Podcast episodes, show notes and references, Ben's Research Reviews Podcast, and a searchable archive that includes all Metabolic Classroom episodes and Research Reviews. Learn more: https://www.benbikman.com Hosted on Acast. See acast.com/privacy for more information.

The SUMMIT trial investigated tirzepatide, a dual GIP and GLP-1 receptor agonist, in 731 patients with HFpEF and obesity. This randomized, placebo-controlled study found that tirzepatide reduced heart failure-related events (HR 0.62, P=0.026) and significantly improved quality of life (KCCQ-CSS +19.5 vs. +12.7, P

West Wellness and Longevity LinksAre you ready to make change but don't know where to start. Book a free 30 min consultation here.https://www.westwellnessatx.com/get-started Have questions? Feel free to reach out to me at: tarawest@westwellnessatx.com Follow me on instagram @westwellnessatxToday, we delve into the intricacies of a novel peptide known as Retatrutide, a compound currently undergoing stage three clinical trials overseen by the FDA and developed by Eli Lilly. This peptide distinguishes itself by functioning as a triple agonist, selectively targeting three critical receptors: GLP1, GIP, and glucagon. The unique mechanism of action of Retatrutide not only aims to regulate blood sugar levels but also to suppress appetite and enhance energy expenditure, thereby presenting a promising therapeutic avenue for managing weight loss and diabetes. Preliminary findings indicate that participants in clinical trials have experienced substantial weight reduction, averaging 24.2% over 48 weeks at the highest dosage. As we explore the multifaceted benefits and potential applications of Retatrutide, we also reflect on the broader implications for individuals struggling with insulin resistance and weight management.Takeaways: The peptide known as Retatrutide, scientifically referred to as LY3437943, is currently undergoing stage three clinical trials under the auspices of the FDA and is developed by Eli Lilly. Retatrutide functions as a triple agonist, effectively targeting three distinct receptors, namely GLP1, GIP, and glucagon, which together facilitate the management of blood sugar levels and appetite suppression. Clinical studies reveal that individuals administered the highest dosage of Retatrutide achieved an impressive average weight loss of approximately 24.2% over a span of 48 weeks, making it a promising option for obesity management. The unique mechanism of Retatrutide distinguishes it from existing treatments, as it simultaneously addresses metabolic and hormonal pathways, presenting a multifaceted approach to weight management and glycemic control. The anticipated completion of clinical trials for Retatrutide is projected around February 2026, although market availability may extend to 2027, indicating a significant wait for potential users. It is imperative that individuals considering the use of Retatrutide engage with a licensed healthcare practitioner to ensure proper guidance and monitoring throughout the treatment process. Links referenced in this episode:westwellnessatx

On this episode of the Top 200 Drugs podcast from Real Life Pharmacology, we cover Percocet, Epogen, quetiapine, glimepiride, and tirzepatide. These are drugs 166-170. Percocet is a combination analgesic. It contains acetaminophen and oxycodone. Pay attention to acetaminophen intake from all sources when patients are on this medication. Epogen (epoetin alfa) stimulates the production of red blood cells. This medication can be useful in treating anemia. Quetiapine (Seroquel) is an antipsychotic. It is often used in patients with hallucinations and delusions associated with Parkinson's disease because it has a lower potential to block dopamine receptors compared to other antipsychotics. Glimepiride is a sulfonylurea. This medication stimulates the release of insulin which can help lower blood sugars in diabetes. Tirzepatide (Mounjaro) is a combination GIP and GLP-1 receptor agonist that can be used for weight loss and the treatment of diabetes.

*TW - Suicide and disordered eating are both briefly mentioned in this episode. Dr. Marguerite Germain is our esteemed guest. She is a board-certified dermatologist and one of the foremost experts in both medical dermatology and aesthetic medicine. Based in Charleston, South Carolina, where she's been voted Best Dermatologist for an incredible 20 consecutive years. She shares with us her personal opinions and medical expertise on topics such as how trauma, stress, hormones, autoimmune disease, viruses (such as COVID) and use of GLP-1 & GIP medications (such as Ozempic, Weygovy, & Mounjaro) can contribute to a decrease in hair & scalp health, skin disease and even nail health. She also shares solutions of how to better care for your hair, skin & nails and support overall health. Visit www.germaindermatology.com to learn more about her practice and shop for products. You can use code GIN20 for a 20% discount on Xtressé - the gummy that supports hair and scalp health. Follow on INSTAGRAM. ______________________________________________________________ We LOVE collecting 5 stars -- Don't forget to follow, leave a review or rating and share Drinking With Gin.

Obesity is one of the most pressing health challenges of our time, with genetic and molecular factors playing a crucial role in how our bodies regulate weight. In this season opener, we explore the science behind obesity, focusing on how hormones, genetics, and brain circuits influence feeding behavior and body weight. Join us for a fascinating discussion about the interplay between molecular biology and real-world health outcomes.Our guest, Dr. Giles Yeo, is a professor of molecular neuroendocrinology at the University of Cambridge and an expert in the genetics of obesity. With decades of research experience, Dr. Yeo dives into how hormones like GLP-1 interact with the brain and how genetic mutations can affect eating behaviors. He also explains the innovative molecular biology techniques his lab uses to map brain circuits and decode the genetic influences on body weight.But this episode isn't all about the lab. Dr. Yeo shares his journey from studying the genetics of Japanese pufferfish to becoming a leading voice in obesity research and science communication. Whether he's decoding how Ozempic works or reflecting on the importance of good science communication, Dr. Yeo's passion for the field—and his knack for making complex topics relatable—shines through. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

This week in business news, Allete is going private in a $6.2B deal, Aeris suffers from financial struggles, and Vestas secures 6, 000 MW in new orders during Q4. Fill out our Uptime listener survey and enter to win an Uptime mug! Register for Wind Energy O&M Australia! https://www.windaustralia.com Sign up now for Uptime Tech News, our weekly email update on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard's StrikeTape Wind Turbine LPS retrofit. Follow the show on Facebook, YouTube, Twitter, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary Barnes' YouTube channel here. Have a question we can answer on the show? Email us! Pardalote Consulting - https://www.pardaloteconsulting.comWeather Guard Lightning Tech - www.weatherguardwind.comIntelstor - https://www.intelstor.com Welcome to Uptime News Flash. Industry news lightning fast. Your hosts, Allen Hall, Joel Saxum, and Phil Totaro discuss the latest deals, mergers, and alliances that will shape the future of wind power. News Flash is brought to you by IntelStor. For market intelligence that generates revenue, visit www.intelstor.com. Allen Hall: First up, the U. S. Federal Energy Regulatory Commission has given its approval for a 6. 2 billion acquisition of Allete. The buyers are the Canadian Pension Plan Investment Board and Global Infrastructure Partners. The company brings significant renewable assets to the table, including Minnesota Power and Allete Clean Energy, which operates over 1, 300 megawatts of wind capacity across seven states. Now, Phil, this has been going on for several months now, but it looks like it's finally climbed that last rung in that ladder to become a private company again. Phil Totaro: Yeah, which I think is interesting and important given who the investors are. Keep in mind that GIP just got gobbled up by BlackRock. And the Canadian Pension Plan Investment Board has been making, you know, boatloads of investments around the world. Not only in Canada. Companies like this, but also individual assets where they are a usually minority but co owner so this is giving them the diversity, it's giving BlackRock and, you know, through GIP you know, more assets in their portfolio, which they, you know, they're obviously making a concerted effort and it's, it's part of their strategy to you know, to build up that, that pipeline. So this is, I believe You know, a total of 1. 3 gigawatts of operational wind with substantially more in, in the pipeline. So, you know, it's a great thing to, to see this happen and, and usually in a take, in a go private deal The reason you want to do that is to kind of sort out some of the financials and, and there's an opportunity that they could, you know, re IPO Allete at some point. I like the move because Joel Saxum: Allete is a, you know, they're not a huge wind operator, but Clean energy, but I know that they've got ambitions to do some more development. So we are bringing in fresh capital. Also Allete's headquarters in Minnesota power is up in Duluth, Minnesota, which is a small town of about 80, people. And this will bring some hope, hopefully bring some jobs in up there and a little bit of an expansion. Allen Hall: Down in South America, Brazilian wind blade manufacturer Aeris has approached its creditors seeking a 60 day extension on upcoming interest payments. The company's financial strain stems from a slowdown in new wind turbine contracts. Leading to mounting pressure on its balance sheet. Now, current financials show a concerning picture with net debt reaching about 550 million reales and a debt to EBITDA ratio of 3. 2. Joel, Sonoma has made acquisition efforts towards Aeris for the last couple of years. Do those offers become more serious on Aeris part as they run into some financial difficulty? Joel Saxum: I think Aeris as a company has to turn to Sonoma as a more and mo...

About two years ago, we released a podcast with Dr. Thomas Wadden of the University of Pennsylvania describing work on a new generation of medications to treat diabetes and obesity. They were really taking the field by storm. Since then, much more is known since many additional studies have been published and so many people have been using the drugs. So many, in fact, the market value of the Danish company, Novo Nordisk, one of the two major companies selling the drugs, has gone up. It is now greater than the entire budget of the country of Denmark. This single company is responsible for about half of Denmark's economic expansion this year. So, a lot of people are now taking the drugs and this is a great time for an update on the drugs. And we're fortunate to have two of the world's leading experts join us: Dr. Wadden, Professor of Psychology and Psychiatry at the University of Pennsylvania School of Medicine and the inaugural Albert J. Stunkard Professor of Psychiatry at Penn. Joining us as well as Dr. Robert Kushner, a physician and professor of medicine at Northwestern University and a pioneer in testing treatments for obesity. Interview Summary Tom, you and I were colleagues at Penn decades ago. And I got frustrated the treatments for obesity didn't work very well. People tended to regain the weight. And I turned my attention to prevention and policy. But you hung in there and I admired you for that patience and persistence. And Bob, the same for you. You worked on this tenacious problem for many years. But for both of you, your patience has been rewarded with what seems to me to be a seismic shift in the way obesity and diabetes can be treated. Tom, I'll begin with you. Is this as big of a deal as it seems to me? Well, I think it is as big of a deal as it seems to you. These medications have had a huge impact on improving the treatment of type 2 diabetes, but particularly the management of obesity. With older medications, patients lost about 7 percent of their starting weight. If you weighed 200 pounds, you'd lose about 15 pounds. That was also true of our best diet and exercise programs. You would lose about 7 percent on those programs with rigorous effort. But with the new medications, patients are now losing about 15 to 20 percent of their starting body weight at approximately one year. And that's a 30-to-40-pound loss for a person who started at 200 pounds. And with these larger weight losses, we get larger improvements in health in terms of complications of obesity. So, to quote a good friend of mine, Bob Kushner, these medications have been a real game changer. Thanks for putting that in perspective. I mean, we're talking about not just little incremental changes in what treatments can produce, which is what we've seen for years. But just orders of magnitude of change, which is really nice to see. So, Bob what are these medications that we're talking about? What are the names of the drugs and how do they work? Well, Kelly, this transformation of obesity really came about by finding the target that is really highly effective for obesity. It's called the gut brain axis. And when it comes to the gut it's starting off with a naturally occurring gut hormone called GLP 1. I think everyone in the country's heard of GLP 1. It's released after we eat, and it helps the pancreas produce insulin, slows the stomach release of food, and reduces appetite. And that's where the obesity story comes in. So pharmaceutical companies have taken this hormone and synthesized it, something similar to GLP 1. It mimics the action of GLP 1. So, you could actually take it and give it back and have it injected so it augments or highlights this hormonal effect. Now, that same process of mimicking a hormone is used for another gut hormone called GIP that also reduces appetite. These two hormones are the backbone of the currently available medication. There's two on the market. One is called Semaglutide. That's a GLP 1 analog. Trade name is Wegovy. Now, it's also marketed for diabetes. Tom talked about how it is used for diabetes and increases insulin. That trade name is Ozempic. That's also familiar with everyone around the country. The other one that combined GLP 1 and GIP, these two gut hormones, so it's a dual agonist, the trade name for obesity is called Zep Bound, and the same compound for diabetes is called Mounjaro. These are terms that are becoming familiar, I think, to everyone in the country. Tom mentioned some about the, how much weight people lose on these drugs, but what sort of medical changes occur? Just to reiterate what Tom said, I'll say it in another way. For Semaglutide one third of individuals are losing 20 percent of their body weight in these trials. For Tirzepatide, it even outpaces that. And I got a third of individuals losing a quarter of their body weight. These are unheard of weight losses. And with these weight losses and these independent effects from weight, what we're seeing in the trials and in the clinic is that blood pressure goes down, blood sugar goes down, blood fats like triglyceride go down, inflammation in the body goes down, because we marked that with CRP, as well as improvement in quality of life, which we'll probably get to. But really interesting stuff is coming out over the past year or two or so, that it is improving the function of people living with congestive heart failure, a particular form called a preserved ejection fraction. We're seeing improvements in sleep apnea. Think of all the people who are on these CPAP machines every night. We're seeing significant improvements in the symptoms of sleep apnea and the apneic events. And lastly, a SELECT trial came out, that's what it was called, came out last year. Which for the very first time, Kelly, found improvements in cardiovascular disease, like having a heart attack, stroke, or dying of cardiovascular disease in people living with obesity and already have cardiovascular disease. That's called secondary prevention. That, Tom, is the game changer. Bob, I'd like to go back to Tom in a minute but let me ask you one clarifying question about what you just said. That's a remarkable array of biological medical benefits from these drugs. Just incredible. And the question is, are they all attributable to the weight loss or is there something else going on? Like if somebody lost equal amounts of weight by some other means, would these same changes be occurring? Those studies are still going on. It's very good. We're thinking it's a dual effect. It's the profound amount of weight loss, as Tom said. Fifteen to 21 to even 25 percent of average body weight. That is driving a lot of the benefits. But there also appear to be additional effects or weight independent effects that are working outside of that weight. We're seeing improvements in kidney function, improvement in heart disease, blood clotting, inflammation. And those are likely due to the gut hormone effect independent of the weight itself. That still needs to be sorted out. That's called a mitigation analysis where we try to separate out the effects of these drugs. And that work is still underway. Tom, one of the most vexing problems, over the decades that people have been working on treatments for obesity, has been long term results. And I'm curious about how long have people been followed on these drugs now? What are the results? And what was the picture before then? How do what we see now compared to what you saw before? The study that Bob just mentioned, the SELECT trial followed people for four years on Semaglutide. And patients achieve their maximal weight loss at about one year and they lost 10 percent of their weight. And when they were followed up at four years still on treatment, they still maintained a 10 percent weight loss. That 10 percent is smaller than in most of the trials, where it was a 15 percent loss. But Dr. Tim Garvey showed that his patients in a smaller trial lost about 15 percent at one year and while still on medication kept off the full 15 percent. I think part of the reason the weight loss in SELECT were smaller is because the study enrolled a lot of men. Men are losing less weight on this medication than women. But to your question about how these results compare to the results of earlier treatment, well with behavioral treatment, diet, and exercise back in the 70s beyond, people lost this 7 or 8 percent of weight. And then most people on average regain their weight over one to three years. And the same was true of medication. People often stopped these earlier medications after 6 to 12 months, in part because they're frustrated the losses weren't larger. Some people were also worried about the side effects. But the long and short is once you stop taking the medication, people would tend to regain their weight. And some of this weight regain may be attributable to people returning to their prior eating and activity habits. But one of the things we've learned over the past 20 years is that part of the weight regain seems to be attributable to changes in the body's metabolism. And you know that when you lose weight, you're resting metabolic rate, which is the number of calories your body burns at rest to maintain basic bodily functions. Your resting metabolic rate decreases by 10 to 15 percent. But also, your energy expenditure, the calories you burn during exercise decreases. And that may decrease by as much as 20 to 30 percent. So, people are left having to really watch their calories very carefully because of their lower calorie requirements in order to keep off their lost body weight. I think one thing these new drugs may do is to attenuate the drop both in resting metabolic rate and energy expenditure during physical activity. But the long and short of it is that if you stay on these new medications long term, you'll keep off your body weight. And you'll probably keep it off primarily because of improvements in your appetite, so you have less hunger. And as a result, you're eating less food. I'd like to come back to that in a minute. But let me ask a question. If a person loses weight, and then their body starts putting biological pressure on them to regain, how come? You know, it's disadvantageous for their survival and their health to have the excess weight. Why would the body do that? Well, our bodies evolved in an environment of food scarcity, and our physiology evolved to protect us against starvation. First, by allowing us to store body fat, a source of energy when food is not available. And second, the body's capacity to lower its metabolism, or the rate at which calories are burned to maintain these basic functions like body temperature and heart rate. That provided protection against food scarcity. But Kelly, you have described better than anybody else that these ancient genes that regulate energy expenditure and metabolism are now a terrible mismatch for an environment in which food is plentiful, high in calories, and available 24 by 7. The body evolved to protect us from starvation, but not from eating past our calorie needs. And so, it's this mismatch between our evolution and our appetite and our body regulation in the current, what you have called toxic food environment, when you can eat just all the time. I guess you could think about humans evolving over thousands of years and biology adapting to circumstances where food was uncertain and unpredictable. But this modern environment has happened really pretty rapidly and maybe evolution just hasn't had a chance to catch up. We're still existing with those ancient genes that are disadvantageous in this kind of environment. Bob back to the drugs. What are the side effects of the drugs? Kelly, they're primarily gastrointestinal. These are symptoms like nausea, diarrhea, constipation, heartburn, and vomiting. Not great, but they're generally considered mild to moderate, and temporary. And they primarily occur early during the first four to five months when the medications are slowly dose escalated. And we've learned, most importantly, how to mitigate or reduce those side effects to help people stay on the drug. Examples would be your prescriber would slow the dose escalation. So. if you're having some nausea at a particular dose, we wait another month or two. The other, very importantly, is we have found that diet significantly impacts these side effects. When we counsel patients on these medications, along with that comes recommendations for dietary changes, such as reducing fatty food and greasy food. Reducing the amount of food you're consuming. Planning your meals in advance. Keeping well hydrated. And very importantly, do not go out for a celebration or go out to meals on the day that you inject or at least the first two days. Because you're not going to tolerate the drug very well. We use that therapeutically. So, if you want to get control on the weekends, you may want to take your injection on a Friday. However, if weekends are your time out with friends and you want to socialize, don't take it on a Friday. Same thing comes with a personal trainer, by the way. If you're going to have a personal trainer on a Monday where he's going to overwork you, don't take the injection the day before. You'll likely be nauseated, you're not eating, you're not hydrating. So actually, there's a lot that goes into not only when to take the dose and how to take the dose, but how to take it to the best ability to tolerate it. Two questions based on what you said. One is you talked about these are possible side effects, but how common are they? I mean, how many people suffer from these? Well, the trials show about 25 to 45 percent or so of individuals actually say they have these symptoms. And again, we ask them mild, moderate, severe. Most of them are mild to moderate. Some of them linger. However, they really do peak during the dose escalation. So, working with your prescriber during that period of time closely, keeping contact with them on how to reduce those side effects and how you're doing out of medication is extremely important. And the second thing I wanted to ask related to that is I've heard that there's a rare but serious potential side effect around the issue of stomach paralysis. Can you tell us something about that? I mentioned earlier, Kelly, that these medications slow gastric emptying. That's pretty much in everybody. In some individuals who may be predisposed to this, they develop something called ileus, and that's the medical term for gastric paralysis. And that can happen in individuals, let's say who have a scleroderma, who have longstanding diabetes or other gastrointestinal problems where the stomach really stopped peristalsis. In other words, it's moving. That's typically presented by vomiting and really unable to move the food along. We really haven't seen much of that. We looked at the safety data in a SELECT trial that Tom mentioned, which was 17,000 individuals, about 8,000 or so in each group. We really did not see a significant increase in the ileus or what you're talking about in that patient population. Okay, thanks. Tom had alluded to this before, Bob, but I wanted to ask you. How do you think about these medicines? If somebody takes them, and then they stop using the medicines and they gain the weight back. Is that a sign that the medicine works or doesn't work? And is this the kind of a chronic use drug like you might take for blood pressure or cholesterol? That's a great way of setting up for that. And I like to frame it thinking of it as a chronic progressive disease, just like diabetes or hypertension. We know that when you have those conditions, asthma could be another one or inflammatory bowel disease, where you really take a medication long term to keep the disease or condition under control. And we are currently thinking of obesity as a chronic disease with dysfunctional appetite and fat that is deposited in other organs, causing medical problems and so on. If you think of it as a chronic disease, you would naturally start thinking of it, like others, that medication is used long term. However, obesity appeared to be different. And working with patients, they still have this sense 'that's my fault, I know I can do it, I don't want to be on medication for the rest of my life for this.' So, we have our work cut out for us. One thing I can say from the trials, and Tom knows this because he was involved in them. If we suddenly stop the medication, that's how these trials were definitely done, either blindly or not blindly, you suddenly stop the medication, most, if not all of the participants in these trials start to regain weight. However, in a clinical practice, that is not how we work. We don't stop medication suddenly with patients. We go slowly. We down dose the medication. We may change to another medication. We may use intermittent therapy. So that is work that's currently under development. We don't know exactly how to counsel patients regarding long term use of the medications. I think we need to double down on lifestyle modification and counseling that I'm sure Tom is going to get into. This is really work ahead of us, how to maintain medication, who needs to be on it long term, and how do we actually manage patients. Tom, you're the leading expert in the world on lifestyle change in the context of obesity management. I mean, thinking about what people do with their diet, their physical activity, what kind of thinking they have related to the weight loss. And you talked about that just a moment ago. Why can't one just count on the drugs to do their magic and not have to worry about these things? Well, first, I think you can count on the drugs to do a large part of the magic. And you may be surprised to hear me say that. But with our former behavioral treatments of diet and exercise, we spent a lot of time trying to help people identify how many calories they were consuming. And they did that by recording their food intake either in paper and pencil or with an app. And the whole focus of treatment was trying to help people achieve a 500 calorie a day deficit. That took a lot of work. These medications, just by virtue of turning down your appetite and turning down your responsiveness to the food environment, take away the need for a lot of that work, which is a real blessing. But the question that comes up is, okay, people are eating less food. But what are they eating? Do these medications help you eat a healthier diet with more fruits and vegetables, with lean protein? Do you migrate from a high fat, high sugar diet to a Mediterranean diet, or to a DASH like diet? And the answer is, we don't know. But obviously you would like people to migrate to a diet that's going to be healthier for you from a cardiovascular standpoint, from a cancer risk reduction standpoint. One of the principal things that people need to do on these medications is to make sure they get plenty of protein. And so, guidance is that you should have about 1 gram of dietary protein for every kilogram of body weight. If you're somebody who weighs 100 kilograms, you should get 100 grams of protein. And what you're doing is giving people a lot of dietary protein to prevent the loss of bodily protein during rapid weight loss. You did a [00:20:00] lot of research with me back in the 80s on very low-calorie diets, and that was the underpinning of treatment. Give people a lot of dietary protein, prevent the loss of bodily protein. The other side of the equation is just physical activity, and it's a very good question about whether these medications and the weight loss they induce will help people be more physically active. I think that they will. Nonetheless for most people, you need to plan an activity schedule where you adopt new activities, whether it's walking more or going to the gym. And one thing that could be particularly helpful is strength training, because strength training could mitigate some of the loss of muscle mass, which is likely to occur with these medications. So, there's still plenty to learn about what is the optimal lifestyle program, but I think people, if they want to be at optimal health will increase their physical activity and eat a diet of fruits and vegetables, leaner protein, and less ultra processed foods. Well, isn't it true that eating a healthy diet and being physically active have benefits beyond their impact on your ability to lose the weight? You're getting kind of this wonderful double benefit, aren't you? I believe that is true. I think you're going to find that there are independent benefits of being physical activity upon your cardiovascular health. There are independent benefits of the food that you're eating in terms of reducing the risk of heart attack and of cancer, which has become such a hot topic. So, yes how you exercise and what you eat makes a difference, even if you're losing weight. Well, plus there's probably the triple one, if you will, from the psychological benefit of doing those things, that you do those things, you feel virtuous, that helps you adhere better as you go forward, and these things all come together in a nice picture when they're working. Tom, let's talk more about the psychology of these things. You being a psychologist, you've spent a lot of time doing research on this topic. And of course, you've got a lot of clinical experience with people. So as people are losing weight and using these drugs, what do they experience? And I'm thinking particularly about a study you published recently, and Bob was a coauthor on that study that addressed mental health outcomes. What do people experience and what did you find in that study? I think the first things people experience is improvements in their physical function. That you do find as you've lost weight that you've got less pain in your knees, you've got more energy, it's easier to get up the stairs, it's easier to play with the children or the grandchildren. That goes a long way toward making people feel better in terms of their self-efficacy, their agency in the life. Big, big improvement there. And then, unquestionably, people when they're losing a lot of weight tend to feel better about their appearance in some cases. They're happy that they can buy what they consider to be more fashionable clothes. They get compliments from friends. So, all of those things are positive. I'm not sure that weight loss is going to change your personality per se, or change your temperament, but it is going to give you these physical benefits and some psychological benefits with it. We were happy to find in the study you mentioned that was conducted with Bob that when people are taking these medications, they don't appear to be at an increased risk of developing symptoms of depression or symptoms of suicidal ideation. There were some initial reports of concern about that, but the analysis of the randomized trials that we conducted on Semaglutide show that there is no greater likelihood of developing depression or sadness or suicidal ideation on the medication versus the placebo. And then the FDA and the European Medicines Agency have done a full review of all post marketing reports. So, reports coming from doctors and the experience with their patients. And in looking at those data the FDA and the European Medicines Agency have said, we don't find a causal link between these medications and suicidal ideation. With that said, it's still important that if you're somebody who's taking these medications and you start them, and all of a sudden you do feel depressed, or all of a sudden you do have thoughts like, maybe I'd be better off if I weren't alive any longer, you need to talk to your primary care doctor immediately. Because it is always possible somebody's having an idiosyncratic reaction to these medications. It's just as possible the person would have that reaction without being on a medication. You know, that, that can happen. People with overweight and obesity are at higher risk of depression and anxiety disorders. So, it's always going to be hard to tease apart what are the effects of a new medication versus what are just the effects of weight, excess weight, on your mood and wellbeing. You know, you made me think of something as you were just speaking. Some people may experience negative effects during weight loss, but overall, the effects are highly positive and people are feeling good about themselves. They're able to do more things. They fit in better clothes. They're getting good feedback from their environment and people they know. And then, of course, there's all the medical benefit that makes people feel better, both psychologically and physically. Yet there's still such a strong tendency for people to regain weight after they've lost. And it just reinforces the fact that, the point that you made earlier, that there are biological processes at work that govern weight and tendency to regain. And there really is no shame in taking the drug. I mean, if you have high blood pressure, there's no shame in taking the drug. Or high cholesterol or anything else, because there's a biological process going on that puts you at risk. The same thing occurs here, so I hope the de-shaming, obesity in the first place, and diabetes, of course, and then the use of these medications in particular might help more people get the benefits that is available for them. I recommend that people think about their weight as a biologically regulated event. Very much like your body temperature is a biologically regulated event, as is your blood pressure and your heart rate. And I will ask people to realize that there are genetic contributors to your body weight. just as there are to your height. If somebody says, I just feel so bad about being overweight I'll just talk with them about their family history of weight and see that it runs in the family. Then I'll talk to them about their height. Do you feel bad about being six feet tall, to a male? No, that's fine. Well, that that's not based upon your willpower. That's based upon your genes, which you received. And so, your weight, it's similarly based. And if we can use medications to help control weight, cholesterol, blood pressure, blood sugar, let's do that. It's just we live in a time where we're fortunate to have the ability to add medications to help people control health complications including weight. Bob, there are several of the drugs available. How does one think about picking between them? Well, you know, in an ideal medical encounter, the prescriber is going to take into consideration all the factors of prescribing a medication, like any other medication, diabetes, hypertension, you name the condition. Those are things like contraindication to use. What other medical problems does the patient have that may benefit the patient. Patient preferences, of course and side effects, safety, allergies, and then we have cost. And I'll tell you, Kelly, because of our current environment, it's this last factor, cost, that's the most dominant factor when it comes to prescribing medication. I'll have a patient walk in my room, I'll look at the electronic medical record, body mass index, medical problems. I already know in my head what is going to be the most effective medication. That's what we're talking about today. Unfortunately, I then look at the patient insurance, which is also on the electronic medical record, and I see something like Medicaid or Medicare. I already know that it's not going to be covered. It is really quite unfortunate but ideally all these factors go into consideration. Patients often come in and say, I've heard about Ozempic am I a candidate for it, when can I get it? And unfortunately, it's not that simple, of course. And those are types of decisions the prescriber goes through in order to come to a decision, called shared decision making with the patient. Bob, when I asked you the initial question about these drugs, you were mentioning the trade name drugs like Mounjaro and Ozempic and those are made by basically two big pharmaceutical companies, Novo Nordisk and Eli Lilly. But there are compounded versions of these that have hit the scene. Can you explain what that means and what are your thoughts about the use of those medications? So compounding is actually pretty commonly done. It's been approved by the FDA for quite some time. I think most people are familiar with the idea of compounding pharmacies when you have a child that must take a tablet in a liquid form. The pharmacy may compound it to adapt to the child. Or you have an allergy to an ingredient so the pharmacy will compound that same active ingredient so you can take it safely. It's been approved for long periods of time. Anytime a drug is deemed in shortage by the FDA, but in high need by the public, compounding of that trade drug is allowed. And that's exactly what happened with both Semaglutide and Tirzepatide. And of course, that led to this compounding frenzy across the country with telehealth partnering up with different compounding pharmacies. It's basically making this active ingredient. They get a recipe elsewhere, they don't get it from the company, they get this recipe and then they make the drug or compound it themselves, and then they can sell it at a lower cost. I think it's been helpful for people to get the drug at a lower cost. However, buyer beware, because not all compounded pharmacies are the same. The FDA does not closely regulate these compounded pharmacies regarding quality assurance, best practice, and so forth. You have to know where that drug is coming from. Kelly, it's worth noting that just last week, ZepBound and Mounjaro came off the shortage list. You no longer can compound that and I just read in the New York Times today or yesterday that the industry that supports compounding pharmacies is suing the FDA to allow them to continue to compound it. I'm not sure where that's going to go. I mean, Eli Lilly has made this drug. However, Wegovy still is in shortage and that one is still allowed to be compounded. Let's talk a little bit more about costs because this is such a big determinant of whether people use the drugs or not. Bob, you mentioned the high cost, but Tom, how much do the drugs cost and is there any way of predicting what Bob just mentioned with the FDA? If the compounded versions can't be used because there's no longer a shortage, will that decrease pressure on the companies to keep the main drug less expensive. I mean, how do you think that'll all work out? But I guess my main question is how much these things cost and what's covered by insurance? Well first how much do the drugs cost? They cost too much. Semaglutide, known in retail as Wegovy, is $1,300 a month if you do not have insurance that covers it. I believe that Tirzepatide, known as ZepBound, is about $1,000 a month if you don't have insurance that covers that. Both these drugs sometimes have coupons that bring the price down. But still, if you're going to be looking at out of pocket costs of $600 or $700 or $800 a month. Very few people can afford that. The people who most need these medications are people often who are coming from lower incomes. So, in terms of just the future of having these medications be affordable to people, I would hope we're going to see that insurance companies are going to cover them more frequently. I'm really waiting to see if Medicare is going to set the example and say, yes, we will cover these medications for anybody with a BMI of 40 or a BMI of 35 with comorbidities. At this point, Medicare says, we will only pay for this drug if you have a history of heart attack and stroke, because we know the drug is going to improve your life expectancy. But if you don't have that history, you don't qualify. I hope we'll see that. Medicaid actually does cover these medications in some states. It's a state-by-state variation. Short of that, I think we're going to have to have studies showing that people are on these medications for a long time, I mean, three to five years probably will be the window, that they do have a reduction in the expenses for other health expenditures. And as a result, insurers will see, yes, it makes sense to treat excess weight because I can save on the cost of type 2 diabetes or sleep apnea and the like. Some early studies I think that you brought to my attention say the drugs are not cost neutral in the short-term basis of one to two years. I think you're going to have to look longer term. Then I think that there should be competition in the marketplace. As more drugs come online, the drug prices should come down because more will be available. There'll be greater production. Semaglutide, the first drug was $1,300. Zepbound, the second drug Tirzepatide, $1,000. Maybe the third drug will be $800. Maybe the fourth will be $500. And they'll put pressure on each other. But I don't know that to be a fact. That's just my hope. Neither of you as an economist or, nor do you work with the companies that we're talking about. But you mentioned that the high cost puts them out of reach for almost everybody. Why does it make sense for the companies to charge so much then? I mean, wouldn't it make sense to cut the price in half or by two thirds? And then so many more people would use them that the company would up ahead in the long run. Explain that to me. That's what you would think, for sure. And I think that what's happened right now is that is a shortage of these drugs. They cannot produce enough of them. Part of that is the manufacturing of the injector pens that are used to dispense the drug to yourself. I know that Novo Nordisk is building more factories to address this. I assume that Lilly will do the same thing. I hope that over time we will have a larger supply that will allow more people to get on the medication and I hope that the price would come down. Of course, in the U. S. we pay the highest drug prices in the world. Fortunately, given some of the legislation passed, Medicare will be able to negotiate the prices of some of these drugs now. And I think they will negotiate on these drugs, and that would bring prices down across the board. Boy, you know, the companies have to make some pretty interesting decisions, don't they? Because you've alluded to the fact that there are new drugs coming down the road. I'm assuming some of those might be developed and made by companies other than the two that we're talking about. So, so investing in a whole new plant to make more of these things when you've got these competitor drugs coming down the road are some interesting business issues. And that's not really the topic of what we're going to talk about, but it leads to my final question that I wanted to ask both of you. What do you think the future will bring? And what do you see in terms of the pipeline? What will people be doing a year from now or 2 or 5? And, you know, it's hard to have a crystal ball with this, but you two have been, you know, really pioneers and experts on this for many years. You better than anybody probably can answer this question. Bob, let me start with you. What do you think the future will bring? Well, Kelly, I previously mentioned that we finally have this new therapeutic target called the gut brain axis that we didn't know about. And that has really ushered in a whole new range of potential medications. And we're really only at the beginning of this transformation. So not only do we have this GLP 1 and GIP, we have other gut hormones that are also effective not only for weight loss, but other beneficial effects in the body, which will become household names, probably called amylin and glucagon that joins GLP 1. And we not only have these monotherapies like GLP 1 alone, we are now getting triagonists. So, we've got GIP, GLP 1, and glucagon together, which is even amplifying the effect even further. We are also developing oral forms of GLP 1 that in the future you could presumably take a tablet once a day, which will also help bring the cost down significantly and make it more available for individuals. We also have a new generation of medications being developed which is muscle sparing. Tom talked about the importance of being strong and physical function. And with the loss of lean body mass, which occurs with any time you lose weight, you can also lose muscle mass. There's drugs that are also going in that direction. But lastly, let me mention, Kelly, I spend a lot of my time in education. I think the exciting breakthroughs will not be meaningful to the patient unless the professional, the provider and the patient are able to have a nonjudgmental informative discussion during the encounter without stigma, without bias. Talk about the continuum of care available for you, someone living with obesity, and get the medications to the patient. Without that, medications over really sit on the shelf. And we have a lot of more work to do in that area. You know, among the many reasons I admire the both of you is that you've, you've paid a lot of attention to that issue that you just mentioned. You know, what it's like to live with obesity and what people are experiencing and how the stigma and the discrimination can just have devastating consequences. The fact that you're sensitive to those issues and that you're pushing to de-stigmatize these conditions among the general public, but also health care professionals, is really going to be a valuable advance. Thank you for that sensitivity. Tom, what do you think? If you appear into the crystal ball? What does it look like? I would have to agree with Bob that we're going to have so many different medications that we will be able to combine together that we're going to see that it's more than possible to achieve weight losses of 25 to 30 percent of initial body weight. Which is just astonishing to think that pharmaceuticals will be able to achieve what you achieve now with bariatric surgery. I think that it's just, just an extraordinary development. Just so pleased to be able to participate in the development of these drugs at this stage of career. I still see a concern, though, about the stigmatization of weight loss medications. I think we're going to need an enormous dose of medical education to help doctors realize that obesity is a disease. It's a different disease than some of the illnesses that you treat because, yes, it is so influenced by the environment. And if we could change the environment, as you've argued so eloquently, we could control a lot of the cases of overweight and obesity. But we've been unable to control the environment. Now we're taking a course that we have medications to control it. And so, let's use those medications just as we use medications to treat diabetes. We could control diabetes if the food environment was better. A lot of medical education to get doctors on board to say, yes, this is a disease that deserves to be treated with medication they will share that with their patients. They will reassure their patients that the drugs are safe. And that they're going to be safe long term for you to take. And then I hope that society as a whole will pick up that message that, yes, obesity and overweight are diseases that deserve to be treated the same way we treat other chronic illnesses. That's a tall order, but I think we're moving in that direction. BIOS Robert Kushner is Professor of Medicine and Medical Education at Northwestern University Feinberg School of Medicine, and Director of the Center for Lifestyle Medicine in Chicago, IL, USA. After finishing a residency in Internal Medicine at Northwestern University, he went on to complete a post-graduate fellowship in Clinical Nutrition and earned a Master's degree in Clinical Nutrition and Nutritional Biology from the University of Chicago. Dr. Kushner is past-President of The Obesity Society (TOS), the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Board of Physician Nutrition Specialists (ABPNS), past-Chair of the American Board of Obesity Medicine (ABOM), and Co-Editor of Current Obesity Reports. He was awarded the ‘2016 Clinician-of-the-Year Award' by The Obesity Society and John X. Thomas Best Teachers of Feinberg Award at Northwestern University Feinberg School of Medicine in 2017. Dr. Kushner has authored over 250 original articles, reviews, books and book chapters covering medical nutrition, medical nutrition education, and obesity, and is an internationally recognized expert on the care of patients who are overweight or obese. He is author/editor of multiple books including Dr. Kushner's Personality Type Diet (St. Martin's Griffin Press, 2003; iuniverse, 2008), Fitness Unleashed (Three Rivers Press, 2006), Counseling Overweight Adults: The Lifestyle Patterns Approach and Tool Kit (Academy of Nutrition and Dietetics, 2009) and editor of the American Medical Association's (AMA) Assessment and Management of Adult Obesity: A Primer for Physicians (2003). Current books include Practical Manual of Clinical Obesity (Wiley-Blackwell, 2013), Treatment of the Obese Patient, 2nd Edition (Springer, 2014), Nutrition and Bariatric Surgery (CRC Press, 2015), Lifestyle Medicine: A Manual for Clinical Practice (Springer, 2016), and Obesity Medicine, Medical Clinics of North America (Elsevier, 2018). He is author of the upcoming book, Six Factors to Fit: Weight Loss that Works for You! (Academy of Nutrition and Dietetics, December, 2019). Thomas A. Wadden is a clinical psychologist and educator who is known for his research on the treatment of obesity by methods that include lifestyle modification, pharmacotherapy, and bariatric surgery. He is the Albert J. Stunkard Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania and former director of the university's Center for Weight and Eating Disorders. He also is visiting professor of psychology at Haverford College. Wadden has published more than 550 peer-reviewed scientific papers and abstracts, as well as 7 edited books. Over the course of his career, he has served on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the U.S. House of Representatives. His research has been recognized by awards from several organizations including the Association for the Advancement of Behavior Therapy and The Obesity Society. Wadden is a fellow of the Academy of Behavioral Medicine Research, the College of Physicians of Philadelphia, the Obesity Society, and Society of Behavioral Medicine. In 2015, the Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.

We're in a new era of obesity medicine, where innovative medications are transforming weight management. Dr. Bass shares the latest updates since our last weight loss episode, including new brands, ongoing shortages, and insights into their long-term effects, like whether people regain weight after stopping these medications. This wave of weight loss is also reshaping the aesthetics industry. Surgical procedures like liposuction and skin removal, along with non-surgical options like RF microneedling, are becoming increasingly popular as people refine their bodies after shedding pounds. Find out: Are compounded medications safe? How can you ensure your prescriptions come from a reliable pharmacy? Why does losing muscle instead of fat pose serious risks? How do these advancements impact bariatric surgery's role? Do studies confirm rebound weight gain after stopping medication? What are Dr. Bass' predictions for the future of weight loss medicine? Links Learn more about tummy tuck and liposuction Learn more about Ultherapy and SculpSure About Dr. Lawrence Bass Innovator. Industry veteran. In-demand Park Avenue board certified plastic surgeon, Dr. Lawrence Bass is a true master of his craft, not only in the OR but as an industry pioneer in the development and evaluation of new aesthetic technologies. With locations in both Manhattan (on Park Avenue between 62nd and 63rd Streets) and in Great Neck, Long Island, Dr. Bass has earned his reputation as the plastic surgeon for the most discerning patients in NYC and beyond. To learn more, visit the Bass Plastic Surgery website or follow the team on Instagram @drbassnyc Subscribe to the Park Avenue Plastic Surgery Class newsletter to be notified of new episodes & receive exclusive invitations, offers, and information from Dr. Bass. 

(Édition de RadioPirate LIVE du 19 décembre 2024 avec Jeff, Gerry et MisterWhite. 0min00 - Jeff discute avec Gerry et MisterWhite du «SPACE» qu'il a fait sur X hier, une fonction qui permet de parler aux utilisateurs de X en direct. 34min36 - Avec Gilles Parent on fait le tour de l'actualité de la semaine en compagnie de Jeff et Gerry. puis GIP test les connaissances musicales du DJ avec un méga quizz. 1h02min58 -Un grand tour de l'actualité de Ian & Frank chez les Pirates avec Jeff et Gerry. 1h29min50 - Gerry l'Aubergsite vous suggère des bulles pour les Fêtes. mais pas n'importe lesquel, un abordable! Voici le Champagne Medot Extra Brut. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this weeks episode of Girls Gone Wellness we talk all about the GLP-1 & GLP-1 + GIP agonist medications such as ozempic, wegovy, mounjaro, and zepbound. We have double board certified Gastroenterologist and Obesity medicine specialist, Dr. Michelle Pearlman on to discuss all the nuances of these medications.We talk about:-Dr. Pearlmans approach to weight loss and nutrition using a truly holistic approach with exercise, diet, and medications-Her unique approach to weight loss as a gastroenterologist-The nitty gritty about these mediations: their use, side effects and how they actually should be and should not be used.You can connect with Dr. Pearlman below:Instagram: @michellepearlmanmdNutrition app: @bytemd.app on instagramHer clinic: @primeinstitute.us on instagramWebsite: www.primeinstitute.usDon't forget to follow us on Instagram @girlsgonewellnesspodcast for updates and more wellness tips. Please subscribe to our podcast and leave a review—we truly appreciate your support. Let's embark on this journey to wellness together!DISCLAIMER: Nothing mentioned in this episode is medical advice and should not be taken as so. If you have any health concerns, please discuss these with your doctor or a licensed healthcare professional.

Dr Jill and Lee Henrikson discuss GLP-1 and GIP, how these diabetes type 2 medications are being used for weight loss. How they work in the body and many other benefits in the body outside of weight loss and glucose control.

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms. In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma. To learn more about the topics in this episode: Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2 Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy See omnystudio.com/listener for privacy information.

“Quartiers de demain” is an international architectural consultation aimed at transforming ten priority neighborhoods in France and designing a more sober, sustainable, aesthetic and supportive living environment.In 2023, the President of the French Republic has announced the creation of an international consultation with designers from all over the world, with the aim of transforming ten priority neighborhoods of the French urban policy (QPV). Applications for the Quartiers de demain consultation opened to designers on November 8, with a deadline of December 16, 2024.The aim is to mobilize architectural, urban and landscaping excellence to create projects that demonstrate the ecological and solidarity-based transition, thus giving birth to the future working-class neighborhoods of the 21st century. Supported by the Groupement d'Intérêt Public (GIP) Europe des projets architecturaux et urbains (Europe of architectural and urban projects), this project is part of the Quartiers 2030 plan. Thirty international teams (three for each site) will be selected in January 2025 to work on the future of urban policy.Jean-Baptiste Marie, Managing Director of GIP, testifies on the podcast. We summarize his speech here. Read by Esther.Image teaser DR © GIP Europe des projets Architecturaux et UrbainsSound engineering : Ali Zogheib___If you like the podcast do not hesitate:. to subscribe so you don't miss the next episodes,. to leave us stars and a comment :-),. to follow us on Instagram @comdarchipodcast to find beautiful images, always chosen with care, so as to enrich your view on the subject.Nice week to all of you ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In oktober is Arjan eigenlijk niet te houden. Dat resulteert dat iedereen onderschikt is aan zijn tempo, schema en planning. Getreuzel wordt niet geduld, want elke seconde telt. Haastig op de fiets en wild om zich heen kijkend racen we naar onze bestemming. Er staat een lange wandeling voor de boeg, maar als het goed is zouden we beloond moeten worden. Dat gebeurt en niet niet zo'n beetje ook! Twee lifers voor Gip. Dus ook al is het gehaast een beetje irritant voor de metgezellen, the juice is worth the squeeze - zoals hij dan zelf zegt... ;)Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Gip is voor het eerst op schier, dus is als een kind zo bij. Een nieuw eiland ontdekken en de verwachtingen zijn hoog. De doelsoort wordt een blauwstaart. We weten het, dat is wel heel hoog gegrepen, maar het is niet ondenkbaar. Bij Arjan is er zelfs een keer eentje op z'n fietsband gaan zitten. Dus je weet maar nooit! Voor de rest is het een beetje inkomen. Arjan heeft wat spannende plekjes de bezocht moeten worden. Eerst goed scouten voordat we toeslaan. Maar het beloofd veel, want er is genoeg te zien! Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist, Dr. Jeff Donovan. As the director of the Donovan Hair Academy, Dr. Donovan is dedicated to educating both the public and hair loss practitioners about the complexities of hair loss. In this episode, Dr. Donovan delves into a fascinating study from JAAD Case Reports, which explores the potential benefits of the diabetes drug terzepatide for treating androgenetic alopecia. This groundbreaking case report suggests that medications targeting insulin resistance could offer new strategies for hair growth. Join Dr. Donovan as he breaks down the study, discusses the implications of using GLP-1/GIP receptor agonists for hair loss, and highlights the importance of understanding the metabolic connections to androgenetic alopecia. Discover how these findings could pave the way for novel treatment approaches and what it means for patients worldwide. Whether you're a practitioner, researcher, or someone affected by hair loss, this episode provides insightful perspectives on the future of hair loss treatment. Tune in to learn more about the potential of terzepatide and similar medications in addressing hair loss challenges.     STUDY REFERENCED Gordon E, Musleh S,  Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep . 2024 Jun 11:50:123-125. doi: 10.1016/j.jdcr.2024.06.001. eCollection 2024 Aug.

Tonight's story to help you fall asleep is The Magic Shop by H.G. Wells. Gip and his father visit a magic shop that claims to use only genuine magic! Glass balls out of ears, rabbits under hats, disappearing acts, is it all fake or is something else going on? Support the podcast and enjoy ad-free and bonus episodes. Try FREE for 7 days on Apple Podcasts. For other podcast platforms go to https://justsleeppodcast.com/supportOr, you can support with a one time donation at buymeacoffee.com/justsleeppodIf you like this episode, please remember to follow on Apple Podcasts or your favourite podcast app. Also, share with any family or friends that might have trouble drifting off.Goodnight! Hosted on Acast. See acast.com/privacy for more information.

Join Dr. Emily Cooper, Andrea Taylor, and Mark Wright on Fat Science as they explore the best GLP-1 drugs for treating Metabolic Syndrome and weight management. Dr. Cooper sheds light on the differences between popular options like Victoza, Ozempic, and Manjaro. Andrea shares her personal journey with these medications, emphasizing their life-changing potential. Mark underscores the importance of consulting knowledgeable doctors and staying informed through science-based education. Key Takeaways: GLP-1 drugs mimic naturally occurring hormones to regulate appetite and metabolism. Victoza and Ozempic are similar in function, while Manjaro targets both GLP-1 and GIP hormones. Medication choice is highly individual and should be tailored to personal health needs and circumstances. Consistent eating patterns and regular check-ups are essential to maintaining balance and a healthy metabolism. Personal stories from Andrea highlight the profound impact these drugs can have on well-being. Resources from the episode: Connect with Dr. Emily Cooper on LinkedIn. Connect with Andrea Taylor on LinkedIn. Connect with Mark Wright on LinkedIn. Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go (and stay!) away. In each episode, we share little-known facts and personal experiences to dispel misconceptions, reduce stigma, and instill hope. Fat Science is committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice. If you have a show idea, feedback, or just want to connect, email info@diabesityinstitute.org.

Someone might switch from semaglutide to tirzepatide to achieve greater weight loss or improve blood sugar control. Tirzepatide has been shown to be more effective for some people because it works on two different hormones, GLP-1 and GIP. This combination can lead to better results in managing weight and overall health.  Additionally, if a person stops losing weight on semaglutide or isn't feeling as much appetite suppression, switching to tirzepatide could provide a new option, especially at higher doses. In this podcast, we'll discuss the feedback from doctors and patients about switching from semaglutide to tirzepatide for weight loss. The experiences shared are quite varied. Here are some common themes based on what healthcare providers and patients reported. 1. Appetite Suppression Patients' Experiences: Some patients report weaker appetite suppression with tirzepatide compared to semaglutide. They mention that they felt more consistently full or experienced less "food noise" (persistent thoughts about food) with semaglutide. Others find tirzepatide equally or more effective at reducing hunger, especially at higher doses (10 mg to 15 mg). They note that their appetite was well-controlled after titrating to these higher doses. Clinicians' Observations: Many clinicians observe that tirzepatide's appetite suppression is dose-dependent, with lower doses (5 mg) sometimes being less effective than semaglutide 2.4 mg, but higher doses (7.5 mg and up) providing stronger suppression. Some clinics report that patients may need more time on tirzepatide for the full appetite-suppressing effects to become noticeable. 2. Weight Loss: Patients' Experiences: Many patients experience greater or more rapid weight loss with tirzepatide, especially when titrated to higher doses (10 mg or more). Some report that they plateaued with semaglutide but started losing more weight after switching to tirzepatide. Others find that their weight loss slows down after switching to tirzepatide, particularly if their tirzepatide dose starts low (e.g., 2.5 or 5 mg), which may take time to match the effects of semaglutide 2.4 mg. Clinicians' Observations: Physicians often report that tirzepatide tends to lead to greater weight loss overall compared to semaglutide, especially when patients reach the higher doses (15 mg). However, individual variability plays a significant role, with some patients responding better to one medication over the other, depending on their metabolic profile and personal response to the medications. 3. Side Effects: Patients' Experiences: Patients commonly note that tirzepatide's side effects are similar to semaglutide, particularly stomach-related symptoms like nausea, vomiting, and diarrhea. However, these effects tend to lessen over time with both medications. On the other hand, some patients may experience more intense side effects with tirzepatide, especially during the titration phase. Clinicians' Observations: Clinics generally find that tirzepatide's tolerability improves when the dose is titrated slowly, starting at 2.5 mg. Jumping directly to higher doses (5 mg or more) can increase the likelihood of nausea and other stomach-related side effects. Long-term side effect profiles are comparable between the two, but some clinics observe that tirzepatide's dual mechanism (GIP + GLP-1) might cause more initial stomach discomfort in certain patients. 4. Patient Preferences: Some patients prefer staying on semaglutide because it effectively curbs their hunger and controls cravings better, even if tirzepatide provides more weight loss. Others favor tirzepatide due to its better results in weight loss and overall improvements in metabolic health, especially once they reach higher doses. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

Imagine waking up refreshed after a full night's sleep, free from the constant interruptions of obstructive sleep apnea (OSA). Now, imagine treating your OSA without relying on a bulky CPAP machine but with a convenient once-weekly injectable medication instead. Enter tirzepatide, the breakthrough peptide originally designed for diabetes and weight loss, is now making waves in treating OSA.  Recent studies reveal that tirzepatide (Mounjaro, Zepbound)  reduces apnea episodes and promotes significant weight loss, tackling one of the root causes of sleep apnea.  In this podcast, we'll talk about the science behind this exciting new study. Tirzepatide is a dual agonist that acts like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 and GIP are hormones naturally produced in the gut.  These hormones are important in regulating blood sugar levels, insulin secretion, and appetite control, which is why tirzepatide was first developed for type 2 diabetes and obesity management. By mimicking these hormones, tirzepatide enhances insulin sensitivity, reduces glucagon levels, and slows gastric emptying, which collectively aids in appetite suppression and promotes significant weight loss. The connection between tirzepatide and obstructive sleep apnea (OSA) lies in its ability to reduce body weight. OSA is often exacerbated by excess fat around the neck and airway, which leads to airway obstruction during sleep.  Weight loss is one of the most effective non-surgical treatments for OSA because it reduces this physical pressure, allowing the airway to stay open during sleep. By helping patients lose a substantial amount of weight, tirzepatide can reduce the severity of OSA symptoms. The latest publication from the New England Journal of Medicine (NEJM) discusses the impact of tirzepatide on obstructive sleep apnea (OSA) in individuals with obesity. Tirzepatide was tested in the SURMOUNT-OSA trial to determine its effect on OSA. The study showed that tirzepatide significantly reduced the severity of OSA over one year. The primary measurement was the Apnea-Hypopnea Index (AHI), which tracks the number of breathing interruptions per hour during sleep. In the trials, participants experienced a reduction in AHI by up to 56% compared to placebo. Additionally, body weight decreased by 16-17%, which is notable since weight loss directly improves OSA symptoms. Beyond the improvements in sleep quality, the study also observed benefits like reduced blood pressure, which could have positive cardiovascular implications for patients with OSA. But, further research is needed to determine whether these improvements lead to long-term reductions in cardiovascular events. Tirzepatide's effectiveness in treating OSA provides a promising new avenue for managing the condition, especially for patients who struggle with conventional therapies like CPAP or want to avoid oral facial surgery.  The full clinical impact of tirzepatide on patient-centered outcomes, such as quality of life and long-term health benefits, is still under investigation. While initial studies show promising improvements in sleep apnea severity and weight loss, more research is needed to fully understand its effects on broader health markers and long-term outcomes.  Additional trials will determine whether these short-term benefits translate into sustained improvements in overall health, quality of life, and reduced risks of associated conditions such as cardiovascular disease​. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

Curious about how tirzepatide can help with weight loss?  From understanding how it works to managing potential side effects, many have questions about this medication.  In this podcast, we'll discuss the top questions to give you a clearer picture of how tirzepatide might fit into your weight loss journey. How does tirzepatide work for weight loss?Tirzepatide, marketed as Zepbound, mimics the action of GLP-1 and GIP, two hormones naturally released by your gut. These hormones are critical in regulating appetite and how much food you consume. By enhancing the feeling of fullness and reducing hunger, tirzepatide helps support weight loss. Specifically, it has the following effects: Slows stomach emptying, helping you feel full longer after meals. Decreases appetite, leading to reduced food intake. Reduces food cravings. Stimulates the pancreas to release more insulin, which lowers blood sugar levels. Reduces the liver's new glucose production, further improving blood sugar control. These combined effects make tirzepatide a powerful tool for weight management and improving metabolic health. 1. How long does it take for tirzepatide to work? In clinical trials, people typically began to notice weight loss around 4 weeks after starting tirzepatide. This is when the medication reaches stable levels in the body. The trial lasted for 72 weeks, and the participants continued to lose weight throughout the study. However, the most significant results were observed during the first 8 to 9 months of treatment. 2. How much weight do people lose with tirzepatide? Tirzepatide is one of the most effective weight-loss treatments available. In clinical trials, people lost, on average, between 15% and 21% of their starting body weight after 72 weeks of treatment.  Additionally, longer treatment with tirzepatide tends to lead to more significant weight loss. People in two different studies lost an average of 25% of their starting body weight when using tirzepatide for an extended period.  3. What's the typical tirzepatide dosage for weight loss? The initial tirzepatide dosage is 2.5 mg once a week for the first 4 weeks. After that, the dose is increased to 5 mg weekly. Most people remain on the 5 mg dose for the long term. If necessary, the dose can be gradually increased. But the increases should be by no more than 2.5 mg at a time, and there should be at least 4 weeks in between each one. The maximum tirzepatide dose is 15mg weekly. 4. How long does tirzepatide stay in your system? Tirzepatide has a half-life of about 5 days, meaning that it takes this amount of time for your body to eliminate half of the medication. This helps determine when a medication starts wearing off and influences its dosing schedule. Since Tirzepatide's half-life is 5 days, it only needs to be injected once weekly. On the other hand, a longer half-life means it takes more time for your body to fully eliminate a medication. In the case of tirzepatide, small amounts of the medication may remain in your system for up to 25 days after a dose. 5. How long do you need to take tirzepatide? The duration of tirzepatide treatment depends on your health and weight loss goals. It's best to work with your healthcare provider to determine a timeline that suits your needs. Keep in mind that tirzepatide is designed for long-term use. Still, it may only be needed temporarily if you're able to adopt and sustain certain lifestyle changes after discontinuing the medication . Research shows that maintaining weight loss with tirzepatide is achievable with continued use. At the end of clinical trials, nearly 90% of participants maintained at least 80% of the weight they lost during the first 8 to 9 months.  If you plan to stop taking tirzepatide, it's important to work with your healthcare provider to develop a strategy to help maintain your weight loss. They can help create a plan to continue important lifestyle changes such as proper nutrition, regular physical activity, stress management, and quality sleep.  6. Can you change your tirzepatide injection day? Yes, you can adjust your tirzepatide injection day if needed (e.g., illness, vacation, side effects), but there are specific guidelines to follow. When switching injection days, make sure there's at least a 3-day (72-hour) gap between two doses. For instance, if you typically inject on Saturdays, you could move it to Tuesday (or another later day in the same week).  It's important to consult your healthcare provider before making this change. They can give you a safe and appropriate schedule based on your circumstances. 7. Can you switch from semaglutide to tirzepatide? Yes, you can switch from semaglutide to tirzepatide if you need additional support with weight management.  Based on your current semaglutide dosage and any side effects you're experiencing, your healthcare provider may begin you on a lower dose of tirzepatide. This approach allows your body to adjust to tirzepatide and helps determine your optimal dose. It's important to note that some individuals transitioning from semaglutide to tirzepatide report that semaglutide remains more effective in various aspects, including appetite suppression, managing food cravings, and achieving weight loss goals.  They often note that semaglutide helps reduce "food noise," or the persistent thoughts about food, more effectively than tirzepatide. This variation in response highlights the individual nature of weight management medications, suggesting that while tirzepatide may work well for many, semaglutide may better address specific needs for others, particularly in controlling cravings and enhancing overall satiety. 8. What are the most common side effects of Tirzepatide? The most frequently reported side effects are nausea and constipation. Less commonly, you might experience other gastrointestinal issues such as indigestion, vomiting, diarrhea, burping, and flatulence. Some people have also reported headache and fatigue. 9. How do I manage constipation on tirzepatide? Drink plenty of fluids to stay hydrated and help prevent constipation. To estimate your daily water intake, take your weight in pounds and divide it by two. This will give you the approximate number of ounces of water you should drink each day. For instance, if you weigh 200 pounds, you should aim for about 100 ounces (or 3 liters) of water daily. This amounts to roughly five 20-ounce bottles of water each day. You should drink more if you live in warmer, humid climates or work outside. Engage in exercise 3-4 times a week to support regular bowel movements. This can be as simple as walking 10 to 15 minutes after each meal.  Get more fiber. If you're a woman, you should consume 25 grams of dietary fiber each day to prevent constipation. You should consume 38 grams of dietary fiber each day if you're a man. Try eating more whole grains, fruits, and vegetables to get more fiber. Beans, nuts, and seeds are also a great source of dietary fiber. Remember that consuming too much fiber is possible, particularly if you increase your intake suddenly. Excessive fiber can cause bloating, gas, and constipation. To avoid these issues, gradually introduce more fiber into your diet.  Consider using Metamucil or a stool softener such as docusate sodium if necessary. But always check with your healthcare provider first. They can make sure it's safe for you to take. 10. How do I manage nausea on tirzepatide? Staying hydrated and eating small meals may help. Try to avoid spicy, greasy, or fried food. These foods can irritate the stomach lining and make nausea worse. If nausea persists or becomes severe, consulting with your healthcare provider is important, as they may recommend anti-nausea medications or adjust your tirzepatide dose.  Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

Allen, Joel, and Phil dissect GE Vernova's restructuring of its offshore wind operations, potentially cutting 900 jobs globally. What will be the implications for the US and international wind energy markets? They also share key insights from the Sandia Blades Workshop, emphasizing the importance of prescriptive operations and digitizing tribal knowledge. Enter to win a bunch of Yeti and StrikeTape swag at https://weatherguardwind.com/yeti! Sign up now for Uptime Tech News, our weekly email update on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard's StrikeTape Wind Turbine LPS retrofit. Follow the show on Facebook, YouTube, Twitter, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary Barnes' YouTube channel here. Have a question we can answer on the show? Email us! Pardalote Consulting - https://www.pardaloteconsulting.comWeather Guard Lightning Tech - www.weatherguardwind.comIntelstor - https://www.intelstor.com Allen Hall: Hello everyone. Joel and I have been traveling across America talking with GE2X wind farm operators about how strike tape can protect their blades against lightning damage. If you work on a GE2X site, you need to visit our new website. weatherguardwind.com/yeti. We'll show you how your turbines can be protected against lightning with Strike Tape, and you can also register to win a nice Yeti Roadie 48 cooler, four Yeti mugs, and some Strike Tape swag. Just visit weatherguardwind.com/yeti. Phil, have you been to the National Toy Hall of Fame in Rochester, New York? Philip Totaro: I have not. Allen Hall: Oh my gosh, you're missing out because they have the finalists, the twelfth finalists for induction into the National Toy Hall of Fame this year. And they include, are you ready? Drum roll please. Balloons, Pokemon cards, your own adventure books, which is a particular kind of interesting book. Hess toy trucks, which we see at Christmas time here in the United States. My Little Pony, which should have been an entrance a long time ago, honestly. How is that not already in there? Exactly my point. Remote control vehicles, stick horses, trampolines, and probably one of Joel's favorite, Transformers. I'm a Transformers fan. Hang on, let's go back to stick horses for a second, because again, how long has this museum been, or Hall of Fame been in business? I mean, are they, they're digging up some pretty legacy toy technology there. Stick horses are back. Have you seen those competitions of, where people are riding the stick horses over a competitive course where they're hopping over things and running around? Philip Totaro: There are some people that think that the United States Is not going in the right direction. I think these people are probably steering us in exactly where we don't need to be. Joel Saxum: Allen, when you said that the Toy Hall of Fame, I looked over at my bookshelf and I have to, I went and grabbed this toy, because to me, this is American Toy Hall of Fame material. This was, this toy was my dad's when he was a kid. And this is the original Mound, Minnesota built Tonka trucks. Allen Hall: I think we all need to take a moment and observe and salute the old Tonka truck. I Philip Totaro: will salute that. Joel Saxum: Working tailgate, I'm telling you, that's it right there. Philip Totaro: That's a toy. Joel Saxum: It even says USA on the tires. Allen Hall: Made out of American steel and the edges are sharp like they should be. I'm Allen Hall and here are this week's top stories. In a significant corporate development, the Spanish government has authorized BlackRock's stake in Natergy. This follows BlackRock's acquisition of GIP, which owns 20. 6 percent of the Spanish energy company. The approval comes with conditions, including support for energy transition projects and maintaining Natergy's headquarters in Spain.

In this episode, we're diving deep into GLP-1 agonists, a topic that has sparked considerable debate within the fitness and health communities. Our special guest, Anthony Castor, brings a wealth of knowledge as the first non-physician to earn a fellowship with the Seed Scientific Research and Performance Institute. Together, we'll address controversies, debunk myths, and uncover the multi-faceted benefits of GLP-1 agonists far beyond their well-known role in weight loss and diabetes management. We'll explore their neuroprotective effects, benefits in managing neurodegenerative diseases like Alzheimer's and Parkinson's, and their surprising impact on cognitive decline, addiction, and ADHD. Moreover, we'll break down complex mechanisms, historical context, and real-world applications in an easily digestible format. Stay tuned as we demystify GLP-1 agonists and reveal how they can enhance not only physical but also mental resilience. Anthony Castor, a health advocate and educator, delves into the intricate world of peptides and their multifaceted benefits.   With a passion for making complex biochemical processes understandable, Anthony focuses on the potent impacts of GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and myelin, among others. By demystifying how these peptides interact and function together, Anthony aims to shift public perception and drive forward significant improvements in health. Known for his use of analogies to clarify scientific concepts, Anthony is committed to educating people on the transformative potential of these sophisticated biochemical tools. Anthony's Website: https://www.castoremethod.com Instagram: https://www.instagram.com/anthonycastore/   Join Duffin Community & Education: https://www.skool.com/endless-evolution-8560/about www.chrisduffin.com

Send us a textResources for the Community:Linkrree with Resources https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________About Provider Spotlight The Provider Spotlight is a new series of shorter episodes featuring doctors and specialists from past sessions—think of it as 'doctor shorts.' With over 25k scripts for Zepbound written weekly, many new subscribers haven't seen our earlier episodes, so this helps them catch up quickly. Thanks for your support! We discuss the GLP-1 GIP medication, Mounjaro, and debate if we think it's the future of obesity treatment. We are joined by our GLP-1 TikTok community guest, Beth, who shares her story and struggles with obesity, PCOS, infertility, and insulin resistance. Beth learned about Mounjaro while exploring her options for gastric sleeve surgery and it's changed her life in so many ways. Our medical specialist this week is Alex Guevara, an Advanced Practice Provider in Primary Care in the UK, specializing in medical weight loss using GLP-1 therapies. He has been at the forefront of GLP-1 information and education for the last few years on social media and manages the World's largest Facebook education groups for those using GLP-1 therapies. Alex also provides guidance and training on medical weight loss for providers both in the UK and the U.S. In addition, he is an avid campaigner against obesity stigma and appears regularly on national press and TV to provide education and expert commentary on medical weight loss. Alex's Facebook support group is: Mounjaro Weight Loss Success______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Support the showKim Carlos @DMFKimonMounjaro on TikTokKat Carter @KatCarter7 on TikTok

In this engaging episode of the HealthiHer podcast, Dr. Amy Brenner delves into a frequently asked question from patients: “What's the difference between semaglutide and tirzepatide?” With the increasing popularity of weight loss treatments, these two medications have emerged as prominent options, and understanding their distinctions can be quite valuable. Semaglutide and tirzepatide are both notable for their role in appetite suppression and weight management, but they have unique mechanisms of action that set them apart. Dr. Brenner explains that semaglutide is a GLP-1 receptor agonist, which means it mimics a hormone that regulates appetite and glucose metabolism. It works by enhancing insulin secretion, reducing appetite, and slowing gastric emptying. On the other hand, tirzepatide is a newer medication that targets both GLP-1 and GIP (gastric inhibitory polypeptide) receptors. This dual-action approach not only helps with appetite control but also improves insulin sensitivity more effectively. Listeners will gain insight into how these mechanisms contribute to their effectiveness and what potential side effects might arise. Dr. Brenner also highlights the practical considerations that guide healthcare providers in choosing between these options for their patients. Factors such as individual patient needs, response to treatment, and side effect profiles play a crucial role in this decision-making process. Additionally, the episode touches on the clinical studies that compare the efficacy and safety profiles of semaglutide and tirzepatide. By the end of the discussion, you will have a clearer understanding of the key differences between these weight loss peptides, their respective benefits, and how they may fit into various treatment plans. Whether you’re considering these options for yourself or seeking to understand more about modern weight management therapies, this episode offers valuable insights and expert opinions. Are weight loss medications right for you? Take our 5 minute quiz: https://dramybrenner.com/semaglutide-in-mason/ like and subscribe!  Instagram- https://www.instagram.com/amybrennermd/ Facebook- https://www.facebook.com/DoctorAmyBrenner YouTube- https://www.youtube.com/c/AmyBrennerMD

As we eat, our gastrointestinal (GI) system releases a host of both local and distant regulators to control the process of digestion. We will begin with the primary hormones, then cover some of the secondary hormones, and lastly discuss how our body senses its intraluminal contents and then subsequently integrates all of the various stimuli it receives. After listening to this AudioBrick, you should be able to: Identify the location, cell type, release stimulus to the endocrine cells, and function of the major gastrointestinal (GI) hormones secretin, cholecystokinin (CCK), gastrin, vasoactive intestinal polypeptide (VIP). Describe in brief the release stimulus and function of the GI regulatory peptides bombesin, GLP-1, GLP-2, ghrelin, leptin, motilin, somatostatin, and gastric inhibitory polypeptide (GIP). Understand how the physical and chemical compositions of luminal contents are sensed and the hormonal responses that then occur. Outline how GI cells integrate multiple regulatory inputs from hormonal and neural inputs to control function. You can also check out the original brick on Gastrointestinal Regulatory Substances  from our Gastrointestinal collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/

This week, we're revisiting an episode from earlier this year. BlackRock chief executive Larry Fink has been on the hunt for the money manager's next “transformational” deal. In January, Fink revealed that he had finally found it with the acquisition of a private capital firm, Global Infrastructure Partners. The FT's US financial editor Brooke Masters and US private capital correspondent Antoine Gara explain why BlackRock wanted GIP, and how this deal sets the agenda for Wall Street this year. Clips from CNBC Plus, send us a question! Behind the Money is teaming up with the FT's Moral Money newsletter to answer your questions about what “responsible” business and finance really looks like in the 21st century. That means topics like sustainability, ESG, diversity and inclusion and clean energy investment. These have become hot-button issues that have recently faced a huge backlash. Tell us, what are the questions you have? To get in touch, record a voice message here: sayhi.chat/0humz We might read out, or play the question from your voicemail with your name, on the show.- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Infrastructure: from investment backwater to a $1tn asset classHow the $12.5bn BlackRock-GIP deal is set to shake up investment managementHow Adebayo Ogunlesi's contrarian bet led to $12.5bn BlackRock tie-up - - - - - - - - - - - - - - - - - - - - - - - - - - On X, follow Antoine Gara (@AntoineGara), Brooke Masters (@brookeamasters) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

CardioNerds (Drs. Richard Ferraro, Gurleen Kaur, and Rupan Bose) discuss the growing epidemic of obesity and dive into the role of its procedural management with Dr. Steve Nissen, Chief Academic Officer at the Cleveland Clinic HVTI and past president of the American College of Cardiology. This is an exciting topic that reflects a major inflection point in cardiovascular care. In this episode, we discuss the importance of addressing obesity in cardiovascular care, as it is a major driver of cardiovascular disease and the progression of associated cardiovascular comorbidities. We look at the role of bariatric surgery and its ability to produce sustained weight loss. Finally, we look into the emerging role of new medical therapies such as GLP1 and GIP agonist medications. Notes were drafted by Dr. Rupan Bose and episode audio was edited by CardioNerds Intern Dr. Atefeh Ghorbanzadeh. This episode was produced in collaboration with the American Society of Preventive Cardiology (ASPC) with independent medical education grant support from Novo Nordisk. See below for continuing medical education credit. Claim CME for this episode HERE. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Procedural Management of Obesity with Dr. Steve Nissen Obesity is associated with adverse cardiovascular outcomes. Returning to a healthy weight can largely prevent the downstream consequences of obesity. Regarding lifestyle modifications, diet alone is insufficient in sustaining prolonged weight loss. It is associated with short-term weight loss, but it is generally necessary to supplement with exercise and activity to ensure sustained weight loss. Bariatric surgery should be considered for patients with BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with obesity-related comorbid conditions who are motivated to lose weight and who have not responded to behavioral treatment with or without pharmacotherapy. New emerging medications, including GLP1 receptor agonists, GIP receptor agonists, and glucagon receptor agonists, are beginning to approach weight loss levels that were previously only seen with bariatric surgery. Further research in this dynamic area is ongoing. Show notes - Procedural Management of Obesity with Dr. Steve Nissen Notes drafted by Dr. Rupan Bose. What is the role of obesity in the burden of cardiovascular disease, and why is it so important for CardioNerds to address it? According to the AHA, approximately 2.8 to 3.5 billion people worldwide are either overweight or obese. It is estimated that by 2030, 30% of people in the US will have a BMI greater than 30. Adipose tissue is associated with cytokine release. Cytokines, in turn, can activate and increase levels of IL-1 beta, IL-6, and CRP, leading to an increased inflammatory state. This pro-inflammatory state then accelerates the rate of cardiovascular disease. Obesity is also associated with significant joint and orthopedic diseases, which further impact patients' quality of life and morbidity. Additionally, obesity is associated with NASH cirrhosis. These adverse liver outcomes hold additional significant systemic implications and morbidity. How do you determine one's goal weight and goal BMI? Is BMI a good standard for measuring obesity? BMI is a variable of both weight and height. However, it cannot differentiate those whose weight is from adipose tissue versus from muscle mass. Therefore, BMI measurements can sometimes be misleading. Waist circumference may be a better measurement standard for obesity and risk assessment. The “apple shape” body type, with more abdominal fat, is associated with higher inflammation and cardiovascular risk than the “pear-shaped” body type, which is where there is more fat deposition in the buttocks a...